5272-86-6

Usage

Uses

Used in Pharmaceutical Synthesis:
4-amino-3,5-dimethyl-pyrazol is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, 4-amino-3,5-dimethyl-pyrazol is utilized as a building block in the creation of compounds that can enhance crop protection and yield.
Used in Dye and Pigment Manufacturing:
4-amino-3,5-dimethyl-pyrazol is employed as a key component in the production of dyes and pigments, where its chemical structure contributes to the color and stability of these products.
Used in Biological Research:
4-amino-3,5-dimethyl-pyrazol is studied for its potential biological activities, such as anti-inflammatory and anti-cancer properties, making it a candidate for further research in the field of medicine.
These applications highlight the diverse utility of 4-amino-3,5-dimethyl-pyrazol, reflecting its importance in the synthesis of various compounds and its potential impact on human health and agricultural practices.

InChI:InChI=1/C5H9N3/c1-3-5(6)4(2)8-7-3/h6H2,1-2H3,(H,7,8)

Upstream product

• 1122-04-9 3,5-dimethyl-4-nitrosopyrazole 
• 14531-55-6 3,5-dimethyl-4-nitro-1H-pyrazole 
• 64-17-5 ethanol 
• 7803-57-8 hydrazine hydrate 
• 60-29-7 diethyl ether 
• 3656-05-1 3,5-dimethyl-4-(phenyldiazenyl)-1H-pyrazole 
• 123-54-6 acetylacetone 
• 6134-57-2 pentane-2,3,4-trione 3-phenylhydrazone 
• 67-51-6 3,5-dimethyl-1H-pyrazole 
• 29917-12-2 Isonitrosoacetylacetone 

Downstream Products

• 673855-17-9 1-(3,5-dimethyl-1H-pyrazol-4-yl)-3-phenyl-thiourea 
• 1228345-54-7 N-(1-(4-fluorobenzoyl)-3,5-dimethylpyrazole-4-yl)-4-fluorobenzamide 
• 1228345-59-2 4-(2,6-dichlorobenzylidene)amino-3,5-dimethylpyrazole 
• 1228345-57-0 N-[1-(4-methylbenzoyl)-3,5-dimethylpyrazole-4-yl]-4-methylbenzamide 
• 1020502-74-2 N-(1-(4-chlorobenzoyl)-3,5-dimethylpyrazole-4-yl)-4-chlorobenzamide 
• 1228345-55-8 N-[1-(4-methoxybenzoyl)-3,5-dimethylpyrazole-4-yl]-4-methoxybenzamide 
• 1228345-56-9 N-[1-(2,6-dichlorobenzoyl)-3,5-dimethylpyrazole-4-yl]-2,6-dichlorobenzamide 
• 161155-32-4 1H,4H-3-carboxy-6-nitropyrazolo<4,3-c>pyrazole 
• 1093634-29-7 M₇₇₉₀-1103 

Relevant academic research and scientific papers

Octanitropyrazolopyrazole: A gem-trinitromethyl based green high-density energetic oxidizer

Environmental concerns demand the replacement of ammonium perchlorate (AP) by a green oxidizer in composite propellants. Herein, we report the synthesis and characterization of a novel green high-density energetic oxidizer octanitropyrazolopyrazole (ONPP). With its high specific impulse (256 s), high density (1.997 g cm-3) and good thermal stability (160 °C), ONPP can potentially replace AP. This journal is

Tuning Isonitrile/Tetrazine Chemistry for Accelerated Deprotection and Formation of Stable Conjugates

The isocyano group is a valuable functionality for bioorthogonal reactions because it rapidly reacts with tetrazines to either form stable conjugates or release payloads from 3-isocyanopropyl groups. Here we provide mechanistic insights into the dissociative steps that follow the initial cycloaddition and analyze how structural modifications affect these processes. Three main outcomes of this study have important implications for designing such groups for bioorthogonal applications. First, anion-stabilizing substituents at C-2 of the 3-isocyanopropyl group promote β-elimination and accelerate deprotection. Second, tetrazines with bulky substituents form stable imine conjugates even with primary isonitriles that are otherwise rapidly hydrolyzed. Third, the elimination step is independent from hydrolysis to the aldehyde and instead can occur directly from the imine intermediate. These findings will allow tuning the structures of tetrazine and isonitrile reactants for application in bioorthogonal ligation and release chemistry.

Pyrazolyl-Imidazolium Ligands, Metal Organic Frameworks Comprising the Same and Method of Preparing the Same

According to the present invention, a metal organic framework comprising a pyrazolyl-imidazolium ligand can be produced by synthesizing a ligand including an imidazolium group as a center and a pyrazole group bonded to either or both of the centers, and using the ligand to produce the metal organic framework comprising a pyrazolyl-imidazolium ligand. The pyrazolyl-imidazolium ligand is chemically or thermally stable and is useful for fuel cell or gas separation.COPYRIGHT KIPO 2018

An antiferromagnetic metalloring pyrazolate (Pz) framework with [Cu12(μ2-OH)12(Pz)12] nodes for separation of C2H2/CH4 mixture

The search for functional metalloring organic frameworks (MROFs) has been of continuous interest in the fields of both molecular rings and metal-organic frameworks (MOFs) due to their importance in many multifunctional applications. Herein, a hierarchical pyrazolate framework MROF-12 with the topology of the Schl?fli symbol {460.66} is reported, which is constructed by an elongated rigid ligand and attractive metalloring cluster nodes [Cu12(μ2-OH)12(Pz)12]. MROF-12 not only adopts the unique functionalities of the metalloring clusters but also inherits the porous properties of MOFs. The large [Cu12(μ2-OH)12(Pz)12] metalloring nodes with the diameter of 12.202 ? endow MROF-12 with excellent stability and antiferromagnetism, and they are bridged by linear pyrazolate ligands (H2NDI) to form micro-mesoporous MROF with permanent porosity. The activated sample MROF-12a can exhibit a relatively high Brunauer-Emmett-Teller/Langmuir surface area (460.7/571.9 m2 g-1) as well as pore volume of 0.240 cm3 g-1. Dynamic fixed bed breakthrough experiments indicate that the separation of C2H2/CH4 or CO2/CH4 mixtures can be efficiently achieved through a column packed with MROF-12a solid.

A 2D Zinc Coordination Polymer Built from the Mono-deprotonated 4,4′-Azobis(3,5-dimethyl-1H-pyrazole) Ligand

4,4′-Azobis(3,5-dimethyl-1H-pyrazole) (H2azbpz) in its mono-deprotonated form as a pyrazole-pyrazolate ligand was assembled together with zinc(II) into the two-dimensional coordination polymer [Zn(Hazbpz)NO3]·1.25DMF with sql-a topology, constituted by the dinuclear {Zn2(μ-pz)2(Hpz)2}2+ secondary building unit. The μ3- bridging mode of the ligand is in analogy to bridging modes observed for 4-(4-pyridyl)pyrazolates ligands. After the removal of the DMF solvent molecules, ethanol can be adsorbed up to a maximum uptake of 276 mg·g–1 at p/p0 = 0.9 in an S-shaped adsorption isotherm, corresponding to two ethanol molecules per [Zn(Hazbpz)NO3] formula unit. The desorption isotherm reveals that only one EtOH is desorbed until p/p0 = 0.4 and the other one remains hydrogen-bonded in the framework until very low pressures.

CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN-RELATED PEPTIDASE 6 (KLK6)

The invention relates to compounds which are suitable for the treatment of a disease associated with kallikrein-like peptidase 6 overexpression and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds or pharmaceutical compositions.

Rationally tuning host-guest interactions to free hydroxide ions within intertrimerically cuprophilic metal-organic frameworks for high OH- conductivity

Hydroxide-anion-exchange membrane fuel cells (HEMFCs) are now considered as one of the most promising green energy-conversion technologies for stationary and mobile applications, showing high fuel conversion efficiency at high pH and low cost due to their ability to operate under basic conditions using non-precious metal catalysts. But one key impediment to commercialization is insufficient hydroxide ion (OH-) conductivity of the central HEM component. Here, we report the development of free OH- anion-containing metal-organic frameworks (FOMOFs) with rationally tunable host-guest interactions for HEMs with high OH- conductivity. Among three solids obtained by post-synthesis treatment of ultrastable MOF FJU-66 with various bases, free OH- anions are observed in FJU-66·[EVIm]OH with strong host-guest interactions between the MOF backbone and guest cations. Despite the lowest OH- concentration, FJU-66·[EVIm]OH exhibits the highest OH- conductivity close to 0.1 S cm-1. The high OH- conductivity achieved suggests the potential application of the FOMOFs for practical HEMs of fuel cells.

Synthesis, structure and properties of neutral energetic materials based on N-functionalization of 3,6-dinitropyrazolo[4,3-c] pyrazole

3,6-Dinitropyrazolo[4,3-c]pyrazole (DNPP, 4) was prepared using an efficient modification process. Various neutral energetic derivatives of DNPP were synthesized from N-functionalization of imide (NH) group. All compounds were fully characterized by 1H and 13C nuclear magnetic resonance spectroscopy, infrared spectroscopy, elemental analysis, and differential scanning calorimetry (DSC). The crystal structures of compounds 4·2H2O, 12 and 15 were confirmed by single-crystal X-ray diffraction, showing extensive hydrogen-bonding. The densities of neutral derivatives ranged from 1.74 to 1.95 g cm-3, and all compounds have positive heats of formation in the range of 18.8 to 863 kJ mol-1. Based on the measured densities and calculated heats of formation, theoretical performance calculations, including detonation pressures (27.1-41.5 GPa) and velocities (7819-9364 m s-1), were carried out using the Gaussian 09 program and Kamlet-Jacobs equations, and they compare favorably with those of TNT and RDX. These properties make them potential and competitive for use as new high energy-density materials.

PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY

The present invention provides a method for identifying a tumor - in a human individual or in an animal - that is susceptible to treatment with a TTK inhibitor, said method comprising: a] providing a sample of a tumor; b] determining the presence of a mutated CTNNB1 gene in said tumor sample, wherein said mutation is located in exon 3 of CTNNB1 and whereby the presence of a mutated CTNNB1 gene indicates that the tumor is susceptible to treatment with a TTK inhibitor. In an alternative aspect, step b] of the above defined method is replaced by the step of determining the presence of a mutated CTNNB1 protein in said tumor sample, wherein said mutation is located in exon 3 of CTNNB1 and whereby the presence of a mutated CTNNB1 protein indicates that the tumor is susceptible to treatment with a TTK inhibitor. In a further alternative, step b] comprises determining an altered expression of a CTNNB1 regulated gene, whereby an altered expression of a CTNNB1 regulated gene indicates that the tumor is susceptible to treatment with a TTK inhibitor.

(5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES

The invention relates to a compound of Formula (I) wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.